How to Enable More Desentias Clinical Trials

The costs around this have become increasingnd competative. The system is quite inefficient in actually identifying targets that could work, because it's very closed. If i'm selling you a drug as a byte company, i actually only have an incentive to show you the good data. So we could run 50 studies on this new kansa drug, and forty eight of them show that it doesn't work,. And two of them shows that it kind of works. One of them is inconclusive. Well, show you the two studies that work, and if you're desperate enough, you'll buy it, and then it might work. But also, based if the data was more open, it